Search results for " Antibiotics"

showing 10 items of 50 documents

Carboplatin and pegylated liposomal doxorubicin for advanced ovarian cancer. Preliminary activity results of the MITO-2 phase III trial

2008

<i>Background:</i> Based on the efficacy of pegylated liposomal doxorubicin (PLD) in relapsed ovarian cancer, we are conducting a phase III study comparing carboplatin plus either paclitaxel or PLD as first-line therapy in advanced ovarian cancer. Because of limited phase I and II data on PLD plus carboplatin in this setting, we conducted an interim activity analysis. <i>Patients and Methods:</i> Patients with stage 1c-IV epithelial ovarian cancer were randomized to carboplatin AUC 5 plus either paclitaxel 175 mg/m<sup>2</sup> or PLD 30 mg/m<sup>2</sup> every 3 weeks for 6 cycles. The interim activity analysis was planned according to a single…

Oncologyarea under curveCancer Researchendocrine system diseasesmedicine.medical_treatmentneoplasmspolyethylene glycolsantibioticsPegylated Liposomal Doxorubicinsurvival analysischemistry.chemical_compoundpaclitaxelmiddle agedantineoplastic agentsNeoplasms Glandular and EpithelialhumansanthracyclinesAntibiotics AntineoplasticadultGeneral Medicineovarian neoplasmsfemale genital diseases and pregnancy complicationsagedovarian cancerfemaleOncologyPaclitaxelcarboplatinlipids (amino acids peptides and proteins)Anthracyclinesmedicine.drugmedicine.medical_specialtyantineoplasticantineoplastic combined chemotherapy protocolsglandular and epithelialdoxorubicinpegylated liposomal doxorubicinInternal medicineanthracyclines; carboplatin; ovarian cancer; paclitaxel; pegylated liposomal doxorubicin; adult; aged; antibiotics antineoplastic; antineoplastic agents; antineoplastic combined chemotherapy protocols; area under curve; carboplatin; doxorubicin; female; humans; middle aged; neoplasm staging; neoplasms glandular and epithelial; ovarian neoplasms; paclitaxel; polyethylene glycols; survival analysis; treatment outcomemedicineDoxorubicinneoplasm stagingAdvanced ovarian cancerChemotherapybusiness.industryCancermedicine.diseaseCarboplatinEndocrinologychemistrytreatment outcomebusinessOvarian cancer
researchProduct

Characterization of the bacterial community isolated from a High Middle Age soil sample dated since 980 AD

2016

Paleomicrobiology ancient samples bacterial community antibiotics secreted proteasesSettore BIO/19 - Microbiologia Generale
researchProduct

Should continuous infusion of β‐lactam antibiotics be the first‐line approach?

1997

PharmacologyContinuous infusionbusiness.industryStaphylococcusFirst lineStreptococcusMicrobial Sensitivity TestsPharmacologyGram-Positive Bacteriabeta-LactamsAnti-Bacterial AgentsDrug Delivery SystemsInjections IntravenousAnimalsHumansMedicinePharmacology (medical)Infusions IntravenousbusinessEnterococcusGram-Positive Bacterial InfectionsBeta lactam antibioticsJournal of Clinical Pharmacy and Therapeutics
researchProduct

Unraveling the functional role of Streptomyces coelicolor trpX, an intriguing small orf

2013

ProteomicsAntibioticsActinomycetesProteomics Actinomycetes Antibiotics
researchProduct

Electrochemotherapy for advanced cutaneous angiosarcoma: A European register-based cohort study from the International Network for Sharing Practices …

2019

Abstract Background Cutaneous angiosarcoma (cAS) is a highly aggressive malignancy that challenges the radicality of surgical treatment. Electrochemotherapy (ECT), a skin-directed treatment based on cytotoxic chemotherapy combined with local electric pulses, may be an intraoperative adjunct and a new opportunity in the therapeutic strategy. This cohort study reports the experience with ECT as an option. Methods Data on patients with locally-advanced/metastatic cAS who underwent ECT between October 2013 and October 2018 at eight European centres were prospectively submitted to the InspECT (International network for sharing practices of ECT) register. Patients received therapy according to th…

Register basedmedicine.medical_specialtyElectrochemotherapySkin NeoplasmsElectrochemotherapyHemangiosarcomaSkin metastasesTumour controlPainKaplan-Meier EstimateMalignancyCutaneous angiosarcomaCohort Studies03 medical and health sciencesBleomycin0302 clinical medicineAntibioticsSkin Ulcermedicine80 and overHumansAngiosarcomaCutaneous angiosarcoma; Electrochemotherapy; Skin metastases; Skin-directed therapies; Tumour control; Aged; Aged 80 and over; Antibiotics Antineoplastic; Bleomycin; Cohort Studies; Electrochemotherapy; Feasibility Studies; Female; Hemangiosarcoma; Humans; Kaplan-Meier Estimate; Middle Aged; Pain; Patient Reported Outcome Measures; Prospective Studies; Registries; Skin Neoplasms; Skin Ulcer; Treatment OutcomePatient Reported Outcome MeasuresProspective StudiesRegistriesSkin-directed therapiesAgedAged 80 and overInternational networkAntibiotics Antineoplasticbusiness.industryGeneral MedicineMiddle Agedmedicine.diseaseAntineoplasticmedicine.anatomical_structureTreatment OutcomeTolerability030220 oncology & carcinogenesisScalpFeasibility Studies030211 gastroenterology & hepatologySurgeryFemaleRadiologybusinessCohort studyInternational journal of surgery (London, England)
researchProduct

Novel Penicillin-Type Analogues Bearing a Variable Substituted 2-Azetidinone Ring at Position 6: Synthesis and Biological Evaluation

2015

The synthesis and the biological activity of novel semi-synthetic β-lactam compounds containing an azetidinone moiety joined to the amino-nitrogen of the (+)-6-aminopenicillanic acid (6-APA) as new antibacterial agents is reported. The synthesized compounds were screened for their in vitro antimicrobial activity against a panel of Gram positive and Gram negative pathogens and environmental bacteria. Tested compounds displayed good antimicrobial activity against all tested Gram positive bacteria and for Staphylococcus aureus and Staphylococcus epidermidis antimicrobial activity resulted higher than that of the reference antibiotic. Additionally, in vitro cytotoxic screening was also carried …

Salmonella typhimuriumCell Survivalmedicine.drug_classStereochemistryStaphylococcusGram-positive bacteriaAntibioticsPenicillanic AcidPharmaceutical ScienceBacillus6-aminopenicillanic acid (6-APA); 2-azetidinone; β-lactam antibiotics; antibacterial; Staudinger reactionMicrobial Sensitivity Testsbeta-Lactamsmedicine.disease_causeArticle6-aminopenicillanic acid (6-APA)Analytical Chemistrylcsh:QD241-441MiceStructure-Activity Relationshiplcsh:Organic chemistryStaphylococcus epidermidisPseudomonasβ-lactam antibioticsDrug DiscoveryEscherichia colimedicineAnimalsPhysical and Theoretical ChemistrybiologyChemistryOrganic ChemistryBiological activitybiology.organism_classificationAntimicrobialAnti-Bacterial AgentsPenicillinantibacterialChemistry (miscellaneous)Staphylococcus aureusNIH 3T3 Cells2-azetidinoneAzetidinesMolecular MedicineStaudinger reactionBacteriamedicine.drugMolecules
researchProduct

A "fat" Streptomycete strain overproduces antibiotics

Streptomyces coelicolor antibiotics proteomic analysis undecylprodigiosin streptorubin B morpho-physiological differentiation fatty acidsSettore BIO/19 - Microbiologia Generale
researchProduct

Hidradenitis suppurativa in surgeons' practice: Prevalence and treatment approach according to the Hurley stage in Latvia

2020

Hidradenitis suppurativa (HS) is a chronic, recurrent, debilitating, and frequently misdiagnosed inflammatory skin disease that often requires surgical intervention. To assess the prevalence of HS patients in surgeons' practice and surgeons' approach to treating HS patients, we created a self-administered, Hurley stage-based questionnaire that was distributed during the Latvian Association of Surgeons meeting. Of the total 60 questionnaires distributed, 56 (93%) were collected and 53 (88%) of them were considered valid. Overall, 73.6% of the surgeons confirmed having seen patients with chronic inflamed suppurative lesions in the skin folds during their practice. Median reported number of HS…

Surgeonsmedicine.medical_specialtybusiness.industryInflammatory skin diseaseGeneral surgeryTopical antibioticsDermatologyGeneral MedicineStage iimedicine.diseaseMultidisciplinary teamLatviaSeverity of Illness IndexHidradenitis Suppurativa030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineSystemic antibiotics030220 oncology & carcinogenesisPrevalencemedicineHumansHidradenitis suppurativaStage (cooking)businessDermatologic Therapy
researchProduct

NovelAmycolatopsis balhimycinabiochemical abilities unveiled by proteomics

2014

Amycolatopsis balhimycina DSM5908 is an actinomycete producer of balhimycin, an analogue of vancomycin, the antibiotic of ‘last resort’ against multidrug-resistant Gram-positive pathogens. Most knowledge on glycopeptide biosynthetic pathways comes from studies on A. balhimycina as this strain, among glycopeptide producers, is genetically more amenable. The recent availability of its genome sequence allowed to perform differential proteomic analyses elucidating key metabolic pathways leading to antibiotic production in different growth conditions. To implement proteomic data on A. balhimycina derived from 2-DE approaches and to identify novel components, a combined approach based on protein …

Whole genome sequencingchemistry.chemical_classificationSpectrometry Mass Electrospray Ionizationmass spectrometry; 1D-electrophoresis; glycopeptide antibiotics; actinomycetes; glutamate dehydrogenaseProteomeBiologyProteomicsMicrobiologyGenomeActinomycetes proteomics 2D-DIGE Mass spectrometryGlycopeptideSynthetic biologyMetabolic pathwayEnzymeBiochemistrychemistryBacterial ProteinsTandem Mass SpectrometryProtein purificationActinomycetalesGeneticsElectrophoresis Polyacrylamide GelMolecular BiologyMetabolic Networks and Pathways
researchProduct

Efficacy and safety of Cyprofloxacin XR 1000mg once daily versus Ciprofloxacin 500mg twice daily in the treatment of complicated urinary tract infect…

2009

The aim of this trial was to compare the efficacy and safety of extended-release ciprofloxacin (CIPRO XR) versus the immediate-release formulation (CIPRO IR) in the treatment of complicated urinary tract infections (UTIs). 212 patients were randomized to CIPRO XR 1,000 mg tablet once daily or CIPROXIN IR 500 mg tablet twice daily. Treatment efficacy was evaluated by bacteriological outcome. Safety was measured by recording adverse events. The rate of bacteriological eradication was 83% in the CIPRO XR group and 75% in the CIPRO IR. the overall incidence of adverse events reported was higher in the CIPRO IR group. The authors conclude that CIPRO XR is a safe and effective treatment for compl…

cUTI ciprofloxacin XR ciprofloxacin iR antibiotics urinary tract infectionSettore MED/24 - Urologia
researchProduct